NCT00083551: UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma
Updated: Sep 27, 2022
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
Sponsor
Collaborator
ClinicalTrials.gov Identifier: NCT00083551
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
First Posted : May 27, 2004
Click here for details on ClinicalTrials.gov
Thalidomide Ara-C BCNU Cisplatin Cytoxan Dexamethasone Doxorubicin Etoposide Filgrastim Recombinant GM-CSF Interferon-alpha-2b Melphalan Vincristine
PMID: 16525139
N Engl J Med; March 2006
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
Location
United States, Arkansas
Principal Investigator:Bart Barlogie, M.D., Ph.D.UAMS